
Please try another search
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Name | Age | Since | Title |
---|---|---|---|
Jonathan D. Brodie | - | - | Chairman of Scientific Advisory Board |
Richard John Daly | 63 | 2015 | President, CEO & Director |
Patrick J. McEnany | 78 | 2002 | Co-Founder & Non-Executive Chairman |
Tamar Thompson | 50 | 2023 | Independent Director |
Robert D. Fechtner | - | - | Member of Scientific Advisory Board |
Eugene M. Laska | - | - | Member of Scientific Advisory Board |
Richard B. Silverman | - | 2010 | Member of Scientific Advisory Board |
Molly Harper | 48 | 2021 | Lead Independent Director |
Daniel Curran | 58 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review